Myopia Control in Children: Comparison of Defocus Incorporated Multiple Segments® Lenses Versus Atropine 0.05% Eyedrops
Key facts
- Who runs it
- Fondation Ophtalmologique Adolphe de Rothschild
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 116 people enrolled
- Started
- 19 Oct 2021
- Ended
- 11 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Defocus Incorporated Multiple Segments® (DIMS®) lenses
- Atropine 0.05% eyedrops
- Monofocal lenses
- Record updated
- 21 August 2026
Who can take part
- Age
- 4 years to 14 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Diagnosis of myopia - measured under cycloplegia - defined by:; A sphere power between -1 and -6 Diopters, on at least one of the two eyes; AND a cylindrical power strictly inferior to 2 Diopters; AND a maximum refractive error strictly inferior to 8 Diopters in the flattest axis
- Not benefiting and never having benefited from a myopia control strategy (orthokeratology, soft defocusing lenses, low concentration atropine eye drops, peripheral defocusing corrective lenses)
- Written consent of both parents
Who cannot take part
- Previous ophthalmologic surgery of the cornea, lens, retina
- History of genetic disease, or general condition suggesting a syndromic myopia (including an axial length greater than 27 mm)
- History of allergy to atropine
- History of severe anaphylaxis
- History of glaucoma or any other chronic ophthalmological disease in the course of treatment (including vernal keratoconjunctivitis)
- Strabismus
- Amblyopia defined by a best corrected visual acuity strictly inferior to 10/10 on one of the two eyes
- Anisometropia defined by a difference of 2 Diopters or more between the two eyes (in spherical equivalent)
- Optical correction with contact lenses
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Myopia is the most common refractive disorder in the world. Many strategies have been developed to control myopia in children. Among them, the instillation of low-concentration atropine eyedrops has been proven to be effective in numerous publications. Nevertheless, the spreading of atropine use is limited by: (1) its uneven availability, (2) a proportion of children with no or poor response, (3) some issues of long-term compliance (4) the possibility of a rebound effect after treatment cessation.
Read full original descriptionShow less
Among the non-drug myopia control strategies, corrective lenses including the Defocus Incorporated Multiple Segments® (DIMS®) technology have demonstrated their effectiveness in a previous study (Hong Kong) when compared to monofocal lenses.
The aim of this study is to compare the efficacy of DIMS lenses alone versus atropine 0.05% eyedrops + monofocal lenses, on the evolution of ocular axial length at 2 years in myopic children.
The 2 groups in the trial
- DIMS®Treatment being tested
Defocus Incorporated Multiple Segments® lenses
Treatment: Defocus Incorporated Multiple Segments® (DIMS®) lenses
- Low-concentration atropine + monofocal lensesExisting treatment, for comparison
Treatment: Atropine 0.05% eyedrops and Monofocal lenses
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Defocus Incorporated Multiple Segments® (DIMS®) Lenses Alone Versus Monofocal Lenses + Atropine 0.05% Eyedrops on the Evolution of Ocular Axial Length at 2 Years in Myopia Control in Children: Single-centre Prospective Randomised Controlled 1:1 Open-label Non-inferiority Study
- Record updated
- 21 August 2026